Erlotinib Effective And With Fewer Side-Effects After First-Line Treatment
Monday, February 28th, 2011Today we offer:
The targeted cancer dose erlotinib has corresponding efficaciousness to chemotherapy, and is ameliorate tolerated, in hard-to-treat cases where a patient’s cancer has progressed chop-chop afterwards discourse with first-line therapy, the results of a new form III run appearance.
Dr Tudor Ciuleanu from the Constitute of Oncology Ion Chiricuta, Cluj-Napoca, Romania, reported this determination from the external COLOSSUS field at the European Multidisciplinary League in Pectoral Oncology (EMCTO), 24-26 February 2011, Lugano, Switzerland.

